Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tuberculosis

Supported pathogenM. tuberculosisMycobacterium tuberculosis

Medicines already documented

Documented evidence

Registered studies whose listed conditions mention “tuberculosis”, “mycobacterium tuberculosis”, “tb”, “latent tb”.

Show all 80

Laboratory measurements against M. tuberculosis recorded in ChEMBL.

Show all 54

Other medicines to investigate

AI prediction · nothing measured

Approved medicines with AI-predicted activity ≥40% against M. tuberculosis that are not already antimicrobials, have no registered study for this condition and have no laboratory record against it. Each shows what it is already used for. They were surfaced computationally for further investigation and are not presented as established treatments for this condition.

M. tuberculosis has 870 repurposing candidates in all. 35 are already listed above, with a registered study for this condition or a laboratory record, so the other 835 are listed here.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Every repurposing candidate for M. tuberculosis, including those with documented evidence →

Registered studies

A registration describes a study; it does not establish a positive result.

When these studies started244 of 249 have a start date · most in 2023 (19)
199420102026

  • The BLAST- 1 Trial - Cephalexin+Amoxicillin-clavulanate for Tuberculosis

    NCT05664568 · start 2023-03-15

    Registered record
    Registry ID
    NCT05664568
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Cephalexin; Amoxicillin-Clavulanate 500 Mg-125 Mg Oral Tablet; Standard of care treatment of tuberculosis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-03-15
    Completion
    2024-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionCephalexin; Amoxicillin-Clavulanate 500 Mg-125 Mg Oral Tablet; Standard of care treatment of tuberculosis
    PhasePhase 2
    Registry statusUnknown

  • Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)

    NCT05401071 · start 2023-01-13

    Registered record
    Registry ID
    NCT05401071
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Short Regimen with Rifapentine 10mg/kg; Standardized Regimen; Short Regimen with Rifapentine 15mg/kg; Short Regimen with Rifapentine 20mg/kg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2023-01-13
    Completion
    2027-11-01
    Enrolment
    2,442

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionShort Regimen with Rifapentine 10mg/kg; Standardized Regimen; Short Regimen with Rifapentine 15mg/kg; Short Regimen with Rifapentine 20mg/kg
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • BPaL(M) Regimen for the Treatment of MDR/RR-TB

    NCT05381194 · start 2022-12-13

    Registered record
    Registry ID
    NCT05381194
    Conditions
    Multidrug- and Rifampicin-resistant Tuberculosis
    Interventions
    BPaL(M) regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-12-13
    Completion
    2027-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultidrug- and Rifampicin-resistant Tuberculosis
    InterventionBPaL(M) regimen
    PhasePhase 4
    Registry statusRecruiting

  • A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098

    NCT05473195 · start 2022-12-06

    Registered record
    Registry ID
    NCT05473195
    Conditions
    Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)
    Interventions
    BVL-GSK098 9mg; Ethionamide 250mg; Ethionamide 250 mg; Isoniazid 300 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-12-06
    Completion
    2024-04-16
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)
    InterventionBVL-GSK098 9mg; Ethionamide 250mg; Ethionamide 250 mg; Isoniazid 300 MG
    PhasePhase 2
    Registry statusCompleted

  • Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines

    NCT05592223 · start 2022-12-06

    Registered record
    Registry ID
    NCT05592223
    Conditions
    Tuberculosis
    Interventions
    BCG Vaccine USP; Isoniazid; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-12-06
    Completion
    2023-12-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionBCG Vaccine USP; Isoniazid; Rifampin
    PhasePhase 1
    Registry statusCompleted

  • Azacytidine During Anti-tuberculosis Therapy

    NCT03941496 · start 2022-10

    Registered record
    Registry ID
    NCT03941496
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Azacitidine Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2022-10
    Completion
    2023-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionAzacitidine Injection
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Linezolid Dosing Strategies in Drug-Resistant TB

    NCT05007821 · start 2022-09-27

    Registered record
    Registry ID
    NCT05007821
    Conditions
    Tuberculosis, Multidrug-Resistant; Tuberculosis; Tuberculosis, Pulmonary
    Interventions
    Linezolid 600 mg; Linezolid 1200 mg (QD); Linezolid 1200 mg (TIW); Bedaquiline 200 mg; Bedaquiline 100 mg; Delamanid 300 mg; Clofazimine 300 mg; Clofazimine 100 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-09-27
    Completion
    2026-01-13
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant; Tuberculosis; Tuberculosis, Pulmonary
    InterventionLinezolid 600 mg; Linezolid 1200 mg (QD); Linezolid 1200 mg (TIW); Bedaquiline 200 mg +4 more
    PhasePhase 2
    Registry statusCompleted

  • Safety of Administering Isoniazid to SLE Patients to Prevent TB

    NCT06618573 · start 2022-08-15

    Registered record
    Registry ID
    NCT06618573
    Conditions
    Tuberculosis; Systemic Lupus Erythematosus
    Interventions
    Isoniazid/Pyridoxine; Saccharum Lactis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2022-08-15
    Completion
    2025-12-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Systemic Lupus Erythematosus
    InterventionIsoniazid/Pyridoxine; Saccharum Lactis
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis

    NCT05382312 · start 2022-07-26

    Registered record
    Registry ID
    NCT05382312
    Conditions
    Tuberculosis
    Interventions
    GSK3036656; Bedaquiline; Delamanid; RIFAFOUR e-275; BTZ-043; Pretomanid; Linezolid; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-07-26
    Completion
    2025-05-27
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionGSK3036656; Bedaquiline; Delamanid; RIFAFOUR e-275 +4 more
    PhasePhase 2
    Registry statusCompleted

  • One-month Latent Tuberculosis Treatment for Renal Transplant Candidates

    NCT05411744 · start 2022-07-01

    Registered record
    Registry ID
    NCT05411744
    Conditions
    Latent Tuberculosis; End Stage Renal Disease; Renal Transplant Candidate for Right Kidney; Renal Transplant Candidate for Left Kidney
    Interventions
    1 month Rifapentine, Isoniazid and Vitamin B6
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2022-07-01
    Completion
    2029-06-30
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis; End Stage Renal Disease; Renal Transplant Candidate for Right Kidney; Renal Transplant Candidate for Left Kidney
    Intervention1 month Rifapentine, Isoniazid and Vitamin B6
    PhasePhase 4
    Registry statusActive not recruiting

  • Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis.

    NCT05258877 · start 2022-06-10

    Registered record
    Registry ID
    NCT05258877
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Plasma samples
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-06-10
    Completion
    2023-09-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionPlasma samples
    PhaseNot recorded
    Registry statusCompleted

  • Triage Test for All Oral DR-TB Regimen (TRiAD Study)

    NCT05175794 · start 2022-05-26

    Registered record
    Registry ID
    NCT05175794
    Conditions
    Drug Resistant Tuberculosis; MDR-TB; XDR-TB; Tuberculosis
    Interventions
    Xpert® MTB/XDR
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-05-26
    Completion
    2025-06-01
    Enrolment
    786

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Resistant Tuberculosis; MDR-TB; XDR-TB; Tuberculosis
    InterventionXpert® MTB/XDR
    PhaseNot recorded
    Registry statusCompleted

  • Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)

    NCT05081401 · start 2022-05-23

    Registered record
    Registry ID
    NCT05081401
    Conditions
    Multidrug Resistant Tuberculosis; Rifampicin Resistant Tuberculosis; Pre-XDR-TB
    Interventions
    Bdq(Lzd)+Lfx(Mfx)+Cfz(Cs)+Pto+E+H+Z; A1; A2a; A2b; A2c; A3; A4; A5; B-SOC; B1
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-05-23
    Completion
    2027-12-01
    Enrolment
    1,050

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultidrug Resistant Tuberculosis; Rifampicin Resistant Tuberculosis; Pre-XDR-TB
    InterventionBdq(Lzd)+Lfx(Mfx)+Cfz(Cs)+Pto+E+H+Z; A1; A2a; A2b +6 more
    PhasePhase 3
    Registry statusRecruiting

  • Whole Genome Sequencing of Tuberculosis for Disease Control in Madagascar

    NCT05406453 · start 2022-05-16

    Registered record
    Registry ID
    NCT05406453
    Conditions
    Tuberculosis
    Interventions
    Whole Genome Sequencing testing
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-05-16
    Completion
    2024-06-30
    Enrolment
    98,362

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionWhole Genome Sequencing testing
    PhaseNot applicable
    Registry statusCompleted

  • A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China

    NCT05306223 · start 2022-05-10

    Registered record
    Registry ID
    NCT05306223
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    Bedaquiline; Levofloxacin; Linezolid; Cycloserine; Clofazimine; Pyrazinamide; Protionamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-05-10
    Completion
    2025-08-08
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionBedaquiline; Levofloxacin; Linezolid; Cycloserine +3 more
    PhasePhase 4
    Registry statusUnknown